Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy
Open Access
- 20 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 33 (7), 875-880
- https://doi.org/10.1093/eurheartj/ehr456
Abstract
Highly active antiretroviral therapy (HAART) dramatically reduces human immunodeficiency virus (HIV)-associated morbidity and mortality, but adverse effects of HAART are becoming an increasing challenge, especially in the setting of acute coronary syndromes (ACS). We thus performed a comprehensive review of studies focusing on ACS in HIV patients. MEDLINE/PubMed was systematically screened for studies reporting on ACS in HIV patients. Baseline, treatment, and outcome data were appraised and pooled with random-effect methods computing summary estimates [95% confidence intervals (CIs)]. A total of 11 studies including 2442 patients were identified, with a notably low prevalence of diabetes [10.86 (4.11, 17.60); 95% CI]. Rates of in-hospital death were 8.00% (2.8, 12.5; 95% CI), ascribable to cardiovascular events for 7.90% (2.43, 13.37; 95% CI), with 2.31% (0.60, 4.01; 95% CI) developing cardiogenic shock. At a median follow-up of 25.50 months (11.25, 42; 95% CI), no deaths were recorded, with an incidence of 9.42% of acute myocardial infarction (2.68, 16.17; 95% CI) and of 20.18% (9.84, 30.51; 95% CI) of percutaneous coronary revascularization. Moreover, pooled analysis of the studies reporting incidence of acute myocardial infarction in patients exposed to protease inhibitors showed an overall significant risk of 2.68 (odds ratio 1.89, 3.89; 95% CI). Human immunodeficiency virus patients admitted for ACS face a substantial short-term risk of death and a significant long-term risk of coronary revascularization and myocardial infarction, especially if receiving protease inhibitors.Keywords
This publication has 49 references indexed in Scilit:
- Chemokine receptor CCR5: from AIDS to atherosclerosisBritish Journal of Pharmacology, 2011
- Acute Coronary Syndromes in Treatment‐Naïve Black South Africans with Human Immunodeficiency Virus InfectionJournal of Interventional Cardiology, 2010
- Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus DiseaseJournal of Clinical Endocrinology & Metabolism, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionThe New England Journal of Medicine, 2007
- Outcome of percutaneous coronary intervention in HIV-infected patientsCatheterization and Cardiovascular Interventions, 2006
- Human immunodeficiency virus infection and macrophage cholesterol metabolismJournal of Leukocyte Biology, 2006
- Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from MacrophagesPLoS Biology, 2006
- Percutaneous coronary intervention in HIV infected patients: immediate results and long term prognosisHeart, 2005
- Clinical characteristics and mid-term prognosis of acute coronary syndrome in HIV-infected patients on antiretroviral therapyHIV Medicine, 2005
- Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus InfectionCirculation, 2004